Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: adoptive T-cell therapies - Eutilex

Next Previous
Drug Profile

Research programme: adoptive T-cell therapies - Eutilex

Alternative Names: CTAG1B-induced natural T cell therapy - Eutilex; HPV 4-1BB CTL - Eutilex; HPV-induced adoptive T cell therapy - Eutilex; HPViNT - Eutilex; Human pappilomavirus-induced natural T cell therapy - Eutilex; Mesothelin 4-1BB CTL - Eutilex; Mesothelin-induced adoptive T cell therapy - Eutilex; Mesothelin-induced natural T cell therapy - Eutilex; MesotheliniNT - Eutilex; NYESOiNT - Eutilex; NYESOiNT 4-1BB CTL - Eutilex

Latest Information Update: 28 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eutilex
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral, Infusion)
  • 06 Nov 2017 Preclinical trials in Cancer in South Korea (Parenteral) before November 2017 (Eutilex pipeline, November 2017)
  • 06 Nov 2017 Eutilex files an IND application for Mesothelin-induced adoptive T cell therapy in Cancer before November 2017 (Eutilex website, November 2017)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top